DSIP
Tissue & recoveryAlso known as Delta sleep-inducing peptide
Evidence tier
Multiple human trials
3 human trials · 1 observational
- Researched since
- 1975
- Publications
- 519
- Mean purity
- 99.6%
- Vendors listing
- 23
Protide Health shows the highest mean assayed purity for DSIP at 100.0% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1975 — 51 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
519 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 18 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.29 pts purity across lots, mean label deviation 11.4%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
23 of 23 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
17 of 18 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is DSIP?
Delta sleep-inducing peptide, a nine–amino-acid peptide first isolated from cerebral blood, studied in relation to sleep regulation and stress responses.
Studied in published research for sleep regulation and stress resilience.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and small human investigations of sleep physiology, with mixed findings. PepIndex does not evaluate clinical significance and does not describe administration.
- Delta sleep-inducing peptide — European journal of anaesthesiology (2001)
Peer-reviewed article indexed in PubMed, published in European journal of anaesthesiology (2001).
- Delta-sleep-inducing peptide (DSIP): a review — Neuroscience and biobehavioral reviews (1984)
Peer-reviewed article indexed in PubMed, published in Neuroscience and biobehavioral reviews (1984).
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle — Journal of neurochemistry (2006)
Peer-reviewed article indexed in PubMed, published in Journal of neurochemistry (2006).
- Delta-sleep-inducing peptide (DSIP): an update — Peptides (1986)
Peer-reviewed article indexed in PubMed, published in Peptides (1986).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity? — Obesity reviews : an official journal of the International Association for the Study of Obesity (2009)
Peer-reviewed article indexed in PubMed, published in Obesity reviews : an official journal of the International Association for the Study of Obesity (2009).
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke — Molecules (Basel, Switzerland) (2021)
Peer-reviewed article indexed in PubMed, published in Molecules (Basel, Switzerland) (2021).
- [Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide] — Medicinski pregled (2008)
Peer-reviewed article indexed in PubMed, published in Medicinski pregled (2008).
Indexed studies4 human-evidence of 4
- DSIP in insomnia — Human — controlled trial, 1984
This paper summarizes different investigations into effects of delta sleep-inducing peptide (DSIP) injections on insomnia. Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep. Repeated administrations indicated a buildup with normalization of sleep structure after four administrations. Repeated injections in the morning - besides increasing daytime activity - still had a strong positive effect on night sleep, but not s…
- Effects of DSIP on narcolepsy — Case report, 1984
Repeated injections of delta sleep-inducing peptide (DSIP) were given to a 35-year-old male narcoleptic. Effects on wakefulness and sleep were evaluated by self-reports, performance tests, multiple sleep latency test and all-night polysomnography. DSIP reduced the frequency of sleep attacks and increased activity, alertness and performance during day-time. The sleep period was compressed by DSIP with enhancement of REM sleep. The results suggest that the effects are due to an…
- A clinical trial with DSIP — Human — controlled trial, 1984
In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months. The mood and performance during the daytime improved as well. A problem may be a long-standing habit of drug addiction.
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Human — controlled trial, 1987
Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placeb…
Evidence digest
What the research on DSIP actually shows
The indexed literature on DSIP includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether DSIP is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 9397% | $4.09 (69%) | 1 | 99.9% | 6.9% | |
| Amino ClubISO/IEC 17025 | 90.495% | $0.70 (30%) | 0 | — | — | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 2 | 99.7% | 22.6% | |
| PeptidePlugs | 89.790% | — | 2 | 99.3% | 12.1% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 1 | 99.9% | 0.0% | |
| Northline LabsISO/IEC 17025 | 87.393% | $5.33 (90%) | 1 | 99.9% | 7.0% | |
| Evo Labs Research | 82.789% | $2.33 (39%) | 1 | 99.4% | 11.2% | |
| NeuroLabs Research | 79.386% | — | 1 | 99.2% | 7.2% | |
| ZC Labs | 79.384% | — | 2 | 99.6% | 7.7% | |
| Licensed Peptides | 7789% | — | 1 | 99.8% | 5.8% | |
| Ascension Peptides | 76.186% | $6.50 (110%) | 1 | 99.7% | 36.8% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.4% | 3.2% | |
| Simple Peptide | 7489% | — | 1 | 99.7% | 19.0% | |
| American PeptidesISO/IEC 17025 | 73.5100% | $11.00 (186%) | 1 | 99.9% | 4.6% | |
| Protide Health | 70.994% | $10.00 (169%) | 1 | 100.0% | 11.9% | |
| Eternal Peptides | 70.865% | $4.50 (76%) | 0 | — | — | |
| True Research Labs | 70.671% | $5.27 (89%) | 0 | — | — | |
| Vertex Labs | 70.170% | — | 1 | 99.0% | 7.0% | |
| Good Science Bio | 68.575% | $7.00 (118%) | 0 | — | — | |
| Mile High Compounds | 67.294% | $5.00 (85%) | 0 | — | — | |
| Improved Peptides | 59.689% | $9.00 (152%) | 0 | — | — | |
| BioLongevity Labs | 59.274% | $11.19 (189%) | 0 | — | — | |
| Evolve Peptides | 55.667% | $9.00 (152%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Vertex Labs | 2608190856 | Freedom Diagnostics Testing | 10 mg | 9.3 mg | 7.0% | 99.0% | Vendor-published | |
| Ascend Science | AS-DSIP5-2 | Kovera Labs and/or ILS Labs | 10 mg | 5.49 mg | 45.1% | 99.7% | Vendor-published | |
| Ascend Science | AS-DSIP10-2 | Kovera Labs | 10 mg | 10.02 mg | 0.2% | 99.7% | Vendor-published | |
| PeptidePlugs | 160-05-DK | Freedom Diagnostics Testing | 10 mg | 11.31 mg | 13.1% | 99.2% | Vendor-published | |
| ZC Labs | ZCLa2607200287 | Freedom Diagnostics Testing | 10 mg | 9.53 mg | 4.7% | 99.8% | Vendor-published | |
| NeuroLabs Research | NL01-DSIP10R | Analysis FreedomDiagnostics | 5 mg | 4.64 mg | 7.2% | 99.2% | Vendor-published | |
| Protide Health | PH-dp10-0322 | Analysis FreedomDiagnostics | 10 mg | 11.19 mg | 11.9% | 100.0% | Vendor-published | |
| Next Gen Peptides | DSIP10-02 | ILS Laboratories | 10 mg | 10.69 mg | 6.9% | 99.9% | Vendor-published | |
| Northline Labs | NLL-6825192 | ILS Laboratories | 10 mg | 10.7 mg | 7.0% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2606260482 | Freedom Diagnostics Testing | 10 mg | 11.06 mg | 10.6% | 99.4% | Vendor-published | |
| American Peptides | DSIP5-0528 | Bioviridian Inc. | 5 mg | 5.23 mg | 4.6% | 99.9% | Vendor-published | |
| PeptidePlugs | 142-03-DK | Freedom Diagnostics Testing | 10 mg | 11.1 mg | 11.0% | 99.5% | Vendor-published | |
| Modern Aminos | BX-P-E7D7 | Analysis FreedomDiagnostics | 5 mg | 5.16 mg | 3.2% | 99.4% | Vendor-published | |
| Simple Peptide | DSIP5-062026-1 | Analysis FreedomDiagnostics | 5 mg | 5.95 mg | 19.0% | 99.7% | Vendor-published | |
| Licensed Peptides | 032520261 | Vanguard Laboratory | 10 mg | 10.58 mg | 5.8% | 99.8% | Vendor-published | |
| Ascension Peptides | 14-01260229 | MZ Biolabs | 10 mg | 13.68 mg | 36.8% | 99.7% | Vendor-published | |
| Evo Labs Research | 0010825 | Evolabs Research | 15 mg | 16.68 mg | 11.2% | 99.4% | Vendor-published | |
| Hydro Research Peptides | DS-Z29TRQ | Janoshik Labs | 5.33 mg | 5.33 mg | 0.0% | 99.9% | Vendor-published |